Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19

Phase 3

Recruiting

Conditions: COVID-19.
Coronavirus infection, unspecified
B34.2

Registration Number: IRCT20120703010178N25

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Confirmed COVID-19, based on reverse transcriptase-polymerase chain reaction (rt-PCR)
Patients with mild to moderate COVID-19
Within 48 hours of the onset of the symptoms

Exclusion Criteria

Age younger than 18 years old
Diagnosis of COVID-19 based on clinical criteria without positive rt-PCR results
The onset of symptoms more than 48 hours
Patients with severe to critical COVID-19
Immunocompromised state
Receiving any antiviral or anti-inflammatory drug
Lactation and pregnancy
Liver enzymes 3 times higher than the normal range
Psychotic disorders
Platelet count below 50,000
Hemoglobin less than 10 grams per deciliter

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body temperature. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: Thermometer.;Systolic blood pressure. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: sphygmomanometer.;Diastolic blood pressure. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: sphygmomanometer.;Respiratory rate. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: chronometer.;Pulse rate. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: chronometer.;Level of oxygen saturation in the peripheral circulation. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: pulse oximeter.

Secondary Outcome Measures

Name	Time	Method
ausea. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: Self reporting.;Abdominal pain. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: Self reporting.;Injection site pain. Timepoint: After 7 days of the treatment. Method of measurement: Self reporting.;Myalgia. Timepoint: In the beginning of the study and after 7 days of the treatment. Method of measurement: Self reporting.